Danish biotech company Adcendo announced on Wednesday that it has received approval from the US Food & Drug Administration (FDA) for its IND application for a Phase I study assessing ADCE-T02 in patients with advanced solid tumours.
Adcendo is conducting a first-in-human Phase I multicentre, open-label, dose escalation study of ADCE-T02, named Tiffany-01, as a monotherapy in patients with advanced solid tumours.
The primary objectives of the study are to determine the maximum tolerated dose and recommended Phase II dose and schedule of ADCE-T02 monotherapy, in addition to assessing ADCE-T02 safety and tolerability. Secondary objectives are to characterise the pharmacokinetics and to evaluate the preliminary efficacy of ADCE-T02.
The study is currently recruiting in Australia and will start recruiting in the United States in the next few months.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval